Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
8-K
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
2 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Oct 23
8-K
Departure of Directors or Certain Officers
25 Sep 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
S-3ASR
Automatic shelf registration
30 Nov 23
S-8
Registration of securities for employees
8 Aug 23
S-3ASR
Automatic shelf registration
24 Jul 23
S-8
Registration of securities for employees
10 Mar 23
S-3ASR
Automatic shelf registration
9 Sep 22
424B5
Prospectus supplement for primary offering
18 Aug 22
424B3
Prospectus supplement
16 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
4 Jun 21
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
14 Apr 21
DEF 14A
Definitive proxy
14 Dec 20
Other
EFFECT
Notice of effectiveness
18 Nov 21
CORRESP
Correspondence with SEC
15 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
EFFECT
Notice of effectiveness
23 Dec 20
CORRESP
Correspondence with SEC
21 Dec 20
UPLOAD
Letter from SEC
21 Dec 20
UPLOAD
Letter from SEC
18 Dec 20
CORRESP
Correspondence with SEC
8 Dec 20
UPLOAD
Letter from SEC
7 Dec 20
EFFECT
Notice of effectiveness
15 Apr 20
Ownership
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Change in insider ownership
1 Apr 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
3
Jennifer Tousignant
14 Feb 24
4
Jennifer Tousignant
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24